Zhi Tong Cai Jing·2026-01-23 02:49Core Viewpoint - The collaboration between Rongchang Biologics and AbbVie is viewed positively, with significant financial implications for Rongchang Biologics, including an upfront payment of $650 million and potential milestone payments totaling up to $4.95 billion [1] Financial Implications - Rongchang Biologics' stock rose nearly 4%, currently trading at HKD 92.3, with a trading volume of HKD 206 million [1] - The collaboration includes a two-digit tiered royalty on net sales outside Greater China, enhancing revenue potential [1] Strategic Outlook - UBS believes AbbVie, as a multinational pharmaceutical company, will facilitate the global expansion of RC148 in both research and commercialization [1] - The upfront payment is expected to improve Rongchang Biologics' net debt situation, with projections indicating the company may achieve breakeven by 2026 due to multiple new drug approvals [1] Rating Adjustment - UBS upgraded Rongchang Biologics' rating from "Neutral" to "Buy," raising the target price from HKD 63.8 to HKD 120 [1]